MedTrace Logo

EZN-2279 in Patients With ADA-SCID

NCT01420627 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2020-04-16

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of EZN-2279 in patients with ADA-deficient combined immunodeficiency currently being treated with Adagen.

Conditions

  • ADA-SCID
  • Adenosine Deaminase Deficiency
  • Severe Combined Immunodeficiency

Interventions

BIOLOGICAL

EZN-2279

Weekly administration of EZN-2279 via IM injection

BIOLOGICAL

Adagen

Sponsors & Collaborators

  • Leadiant Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Elie Haddad, MD, PhD · Université de Montréal

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-24
Primary Completion
2018-04-10
Completion
2019-05-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01420627 on ClinicalTrials.gov